Exagen Inc. (XGN) Stock Price & Analysis

Exagen Inc. (XGN) rose 0.53% to USD 7.58 as of September 8, 2026 at 12:44 UTC, according to Nexqual real-time market data.

XGN last closed at USD 7.58; the session ranged USD 7.38–7.62 on volume of 138,172 shares. Market capitalization is —, with a 52-week range of USD 2.59–12.23 (NGM). Source: Nexqual, September 8, 2026 at 12:44 UTC.

Key Statistics (as of September 8, 2026 at 12:44 UTC)

Technical Analysis (XGN)

Nexqual's technical model rates XGN "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 12:44 UTC.

From Exagen Inc.'s Latest SEC 10-K Filing (filed 2026-03-10)

Key Strengths & Strategy (as disclosed to the SEC)

• Our laboratory is certified for performance of high-complexity testing by the Centers for Medicare & Medicaid Services (CMS) in accordance with CLIA and is licensed by California and all states requiring out-of-state licensure, including the New York Department of Health (NYSDOH).
• The research projects we support are those that we believe will have a competitive advantage (such as using proprietary technology), a pathway for reimbursement and an established evidence development plan with sufficient market size.
• Our Proprietary Technologies We believe the competitive advantage for our testing products is supported by two core proprietary technologies: our AVISE ® Lupus platform, which incorporate Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE and a set of three biomarkers, the t-cell based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into our AVISE ® CTD product.
• We believe the availability of complement biomarkers combined with our proprietary algorithmic interpretations, as a support or replacement of standard C3 and C4 measures, is of great value for rheumatologists and their patients.

Partnerships

• We believe there is significant potential to capitalize on our proprietary technologies by integrating with commercially validated biomarkers to develop testing products with superior clinical utility, on our own or through collaboration with partners.
• We believe there is significant potential to enhance existing or develop new testing products with superior clinical utility, on our own or through collaboration with partners. ▪ Lupus Nephritis (LN) Biomarkers .

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 12:44 UTC. This page is informational and not investment advice.